A $600 million patent licensing dispute over the use of Botox to treat migraine headaches has been resolved in Allergan PLC’s favor with a U.S. judge scolding Miotox LLC for making “tedious and convoluted” arguments to prove its case.
A $600 million patent licensing dispute over the use of Botox to treat migraine headaches has been resolved in Allergan PLC’s favor with a U.S. judge scolding Miotox LLC for making “tedious and convoluted” arguments to prove its case.
Prometheus IP is a leading intellectual property service enterprise offering competent and economic Intellectual Property Rights (IPR) solutions which include Patents, Designs, Copyrights and Trademarks.